An anti-glypican-3 antibody comprising one or more amino acid substitutionsintroduced in the Fc region is disclosed. Preferably, in the anti-glypican-3antibody, one or more of the amino acid residues at the positions 239, 298,326, 330 and 332 in the Fc region are substituted with other amino acidresidues. Since the Fc-modified anti-glypican-3 antibody of the inventionexhibit enhanced ADCC activity, it is useful in treating cancers, such ashepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptablecarrier, as well as a method of treating a patient with cancer comprisingadministering to the patient the anticancer agent of the invention.
